



ERIC HOLCOMB, GOVERNOR
STATE OF INDIANA

Office of Medicaid Policy and Planning
MS 07, 402 W. WASHINGTON STREET, ROOM W382
INDIANAPOLIS, IN 46204-2739

MEETING AGENDA AND PUBLIC NOTIFICATION

Therapeutics Committee
February 7, 2020
11:00 A.M.

Conference Center Room "A"

Indiana State Government Center South

1. Call to Order-Chair
2. Preferred Drug List: Therapeutic Class Re-Review - Discussion and Recommendations
3. Preferred Drug List: Therapeutic Class Re-Review
 - a) Respiratory
 - i. Antihistamine-Decongestant Combinations/2nd Generation Antihistamines
 - ii. Antiviral Monoclonal Antibodies
 - iii. Beta Adrenergics and Corticosteroids
 - iv. Beta Agonists
 - v. Bronchodilator Agents - Beta Adrenergic and Anticholinergic Combinations
 - vi. Leukotriene Receptor Antagonists
 - vii. Monoclonal Antibodies for the Treatment of Respiratory Conditions
 - viii. Nasal Antihistamines/Nasal Anti-Inflammatory Steroids
 - ix. Oral Inhaled Glucocorticoids



- x. Phosphodiesterase-4 Inhibitors
- xi. Pulmonary Antihypertensives

b) Anti-Infectives

- i. Antivirals - Anti-Herpetic Agents
- ii. Antivirals - Influenza Agents
- iii. Cephalosporins - 3rd Generation
- iv. Fluoroquinolones
- v. Hepatitis C Agents
- vi. Macrolides
- vii. Ophthalmic Antibiotics
- viii. Ophthalmic Antibiotics/Corticosteroid Combinations
- ix. Oral Non-Systemic Antifungals
- x. Otic Antibiotics
- xi. Systemic Antifungals
- xii. Topical Antifungals
- xiii. Topical Antivirals
- xiv. Topical Antivirals and Anti-Inflammatory Steroid Combinations
- xv. Vaginal Antimicrobials

c) Cardiovascular

- i. Angiotensin-Converting Enzyme (ACE) Inhibitors
- ii. ACE Inhibitor Combinations
- iii. Alpha Adrenergic Blockers
- iv. Angiotensin II Receptor Antagonists (ARBs)
- v. ARB Combinations
- vi. Beta Adrenergic Blockers
- vii. Beta Adrenergic Blockers with Diuretics
- viii. Calcium Channel Blockers (CCBs)
- ix. CCBs with HMG-CoA Reductase Inhibitors
- x. Miscellaneous Cardiac Agents

d) Lipotropics

- i. Bile Acid Sequestrants
- ii. Fibrin Acid Derivatives
- iii. HMG-CoA Reductase Inhibitors
- iv. Lipotropics

e) Antimigraine Agents

f) Electrolyte Depleters

g) Multiple Sclerosis Agents

h) CNS and Others

- i. Agents for the Treatment of Opiate Addiction

4. Public Comment

5. Other Business

6. Adjourn